| Name | Title | Contact Details |
|---|
New York City Center is Manhattan’s first performing arts center, established in 1943 with the goal of making theater, dance, and music accessible to all. Located in a distinctive Neo-Moorish building, it has played a significant role in the cultural life of New York City. The center presents a variety of performing arts programming, focusing on dance and musical theater, and hosts notable series such as the Fall for Dance Festival and the Tony-honored Encores! series. The venue features a 2,557-seat mainstage, two smaller theaters, and four studios, allowing for a diverse range of performances. It serves as a home for the Manhattan Theatre Club’s Off-Broadway productions and showcases internationally acclaimed artists and companies. New York City Center is committed to accessibility and inclusivity, engaging audiences across all five boroughs and supporting educational initiatives that reach thousands of students and families each year.
Ondaro, formerly known as Cask NX, is a business and technology consulting firm based in the USA. Founded in 2004, the company has a team of approximately 51-200 employees. Ondaro focuses on helping organizations enhance their operations and achieve growth through technology-driven solutions. The firm specializes in a variety of services centered around the ServiceNow platform. These include business and technology consulting to optimize operations, the development of ServiceNow-based applications that improve user experiences, and the integration of Generative AI to boost productivity. Ondaro also offers HR service delivery solutions with their product "Cask HR Essentials," which automates HR processes, and provides asset data migration services to facilitate efficient transitions to ServiceNow. Ondaro serves a diverse clientele, including state agencies and global manufacturers, helping them modernize operations and improve efficiency through strategic technology initiatives. The company positions itself as a partner for organizations looking to leverage advanced technology solutions for business transformation.
Verdegard offers a complete suite of innovative, integrated, and concierge-level services. Plan designs include PPO options, reference-based, level funded, and hybrid plans which provide unique transparency, patient advocacy, and cost containment options to maximize the benefits and savings.
CoinPayments is the easiest, fastest, and most secure way for merchants worldwide to transact in cryptocurrencies. It is the first and largest cryptocurrency payment processor with more than US $10 billion in total payments to date while supporting more than 2,100 coins on its platform. It is the preferred crypto payment solution for merchants and eCommerce platform providers worldwide. Founded in 2013, CoinPayments is dedicated to providing clients with fast, secure, and user-friendly crypto payment APIs, shopping cart plugins, digital wallets, and a host of other solutions supporting cryptocurrency payment applications.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.